Fat LossMedium Risk
Liraglutide
Also known as: Victoza, Saxenda
- Half-life:
- 13 hours
Administration Routes
subcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
A GLP-1 receptor agonist used for weight management and type 2 diabetes. Reduces appetite and promotes significant fat loss.
Primary Research Areas
- appetite suppression
- weight loss
- blood sugar regulation
Risk Profile
Medium Risk
Moderate risk profile in research contexts. Consult a healthcare professional before use.
Regulatory Status
Prescription OnlyFDA Approved
FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only.
Effective: January 25, 2010View FDA source →
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.